Orion (ORNBV) Q3 2024 earnings summary

Executive summary

• Net sales for January–September 2024 rose 27.6% year-over-year to EUR 1,108.0 million, with operating profit up 77.9% to EUR 323.8 million, driven by strong growth in Nubeqa®, Easyhaler®, Animal Health, and EUR 130 million in milestone payments.

• Nubeqa® became a blockbuster, surpassing EUR 1 billion in in-market sales, and contributed a EUR 70 million milestone; MSD agreement transition added EUR 60 million.

• Cash flow from operating activities per share more than doubled year-over-year.

• Excluding major milestones, net sales increased 16.6% and operating profit 27.5% year-over-year.

• Key R&D events included the termination of the ODM-111 program and discontinuation of ganaxolone after a failed phase III trial, while the ARANOTE trial for darolutamide met its primary endpoint.

Financial highlights

• Q3 2024 net sales increased 56.5% year-over-year to EUR 471.3 million, with operating profit more than doubling to EUR 202.0 million, both boosted by milestone payments.

• Excluding major milestones, net sales for January–September 2024 increased 16.6% to EUR 978.0 million, and operating profit rose 27.5% to EUR 193.8 million.

• Operating profit margin improved to 29.2% for the nine-month period, up from 21.0% a year earlier.

• Profit for the period was EUR 256.5 million (+81.1% year-over-year); basic EPS was EUR 1.83 (+80.9%).

• Cash flow from operating activities reached EUR 204.6 million, up from EUR 70.2 million a year earlier.

Outlook and guidance

• 2024 net sales expected at EUR 1,470–1,510 million and operating profit at EUR 370–400 million, both upgraded during the period.

• EBIT and sales growth targets for 2024–2028 remain unchanged despite R&D reallocations and project terminations.

• Outlook includes EUR 70 million Nubeqa® milestone and EUR 60 million from MSD contract conversion; no other material one-offs included.